Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease

SILA produces a valid estimate of time-from-amyloid positivity in ADAD. This work allows for disease stage in ADAD to be compared to staging for broad forms of AD, which was not previously possible using EYO. However, this work also illustrates that there is a high degree of heterogeneity in preclinical disease duration that is not explained by amyloid alone.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_103008
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease

Nicole S. McKay, Tobey J. Betthauser, Jeremy F. Strain, Zahra Shirzadi et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease

Nicole S. McKay, Tobey J. Betthauser, Jeremy F. Strain, Zahra Shirzadi, David Fernando Aguillon, Johannes Levin, Peter R Millar, Alisha Daniels, Stephanie A. Schultz, Matthew Zammit, Julie K. Wisch, Patricio Chrem, J.R Lee, Eric McDade, Beau M. Ances, Natalie S. Ryan, Jasmeer P. Chhatwal, Jorge J. Llibre‐Guerra, Bradley T Christian, Mathias Jucker, Laura Ibanez, Nelly Joseph‐Mathurin, Charlene Supnet‐Bell, Lisa Vermunt, Guoqiao Wang, Gregory S Day, Yan Li, Robert A. Koeppe, Chengjie Xiong, Carlos Cruchaga, Jee Hoon Roh, Brian A. Gordon, Tammie L.S. Benzinger, Alan E. Renton, Nicolas R. Barthélemy, Suzanne E. Schindler, Clifford R. Jack, John C. Morris, The Dominantly Inherited Alzheimer Network (DIAN), Randall J. Bateman
article en

Abstract

SILA produces a valid estimate of time-from-amyloid positivity in ADAD. This work allows for disease stage in ADAD to be compared to staging for broad forms of AD, which was not previously possible using EYO. However, this work also illustrates that there is a high degree of heterogeneity in preclinical disease duration that is not explained by amyloid alone.

Alzheimer s & DementiaVol. 21(S2)
Ulsan College (KR), Brigham and Women's Hospital (US), University of Wisconsin–Madison (US), Harvard University (US), Washington University in St. Louis (US), University of Michigan (US), German Center for Neurodegenerative Diseases (DE), Jacksonville College (US), Asan Medical Center (KR), LMU Klinikum (DE), Universidad de Antioquia (CO), University of Ulsan (KR), Massachusetts General Hospital (US), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (AR), Amsterdam Neuroscience (NL), Hope Center for Neurological Disorders (US), Mayo Clinic in Arizona (US), UK Dementia Research Institute (GB), Mayo Clinic in Florida (US), Wisconsin Division of Public Health (US), University College London (GB), Ludwig-Maximilians-Universität München (DE), Vrije Universiteit Amsterdam (NL), Icahn School of Medicine at Mount Sinai (US)
Quality Education
Openalex Percentile: Top 33%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.